IGMS Earnings Prediction
The chart below shows how IGMS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IGMS sees a -4.20% change in stock price 10 days leading up to the earnings, and a -2.71% change 10 days following the report. On the earnings day itself, the stock moves by +7.17%. This data can give you a slight idea of what to expect for the next quarter's release.
IGMS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
372.00K
--
12.39%
Gross Margin
--
--
--
Operating Margin
-15124.73%
--
-17.27%
Net Margin
-14133.33%
--
-19.39%
EPS
-1.19
-20.67%
-9.85%
No Data Available
IGMS Earnings Analysis
IGM Biosciences, Inc. Corporation (IGMS.O) Earnings Conference Call
Positive
Positive Point:
- IGM Biosciences had a transformational year in 2022, with a collaboration with Sanofi to develop novel IgM agonist antibodies and progress in clinical development of IGM-8444 for colorectal cancer treatment.
- The company treated the first patient in a randomized clinical study of IGM-8444 in second-line colorectal cancer, aiming for a significant improvement in progression-free survival.
- Progress was made in understanding the role of T-cell engagers like imvotamab in treating autoimmune diseases, with expanded safety and efficacy data showing promise.
- The company treated the first patients in studies of IGM-7354, an IgM targeted immunostimulatory IL-15 cytokine, and IGM-2644, a next generation CD38 antibody for multiple myeloma.
- Plans are in place to file investigational new drug applications and initiate clinical studies for imvotamab in multiple autoimmune diseases, starting with lupus and rheumatoid arthritis.
Negative
Negative:
- The company reported a net loss of $52.6 million in the fourth quarter of 2022, with a full-year net loss of $221.1 million, translating to a loss of $1.19 and $5.32 per share, respectively.
- Research and development expenses for the full year of 2022 were $179.3 million, and general and administrative expenses were $49.7 million for the same period.
- Collaboration revenues for the full year of 2022 were only $1.1 million, indicating limited revenue generation.
- The company forecasts GAAP operating expenses between $290 million and $300 million for full-year 2023, with an expected cash balance of approximately $200 million by the end of the year.
- The decision to redirect clinical development efforts for Imvotamab to focus on autoimmune diseases and cease further monotherapy development in non-Hodgkin's lymphoma may limit immediate revenue potential.
